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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
“probiotic supplementation helps decrease pain and number of tender joints in adults with 
rheumatoid arthritis?”  
 
STUDY DESIGN: Review of three double-blind, randomized control trials published between 
2008 and 2018. All studies were published in English in peer reviewed journals. 
 
DATA SOURCES: Three double-blind, randomized control trials were found via PubMed.  
 
OUTCOMES MEASURED: The outcomes measured included number of tender joints from 
baseline to end of study counted by an investigator, visual analog scale (VAS) for pain severity, 
and a Stanford Health Assessment Questionnaire visual analog scale (HAQ VAS) for pain 
severity.  
 
RESULTS: Two of the three articles found a statistically significant reduction in either patient 
pain or number of tender joints. Alipour et al.  found a mean statistical decrease in 0.72 tender 
joints. Mandel et al.  found a 19.8% decrease in patient pain compared to a 1.6% reduction in 
pain in the placebo group. Zamani et al.  found no statistically significant effect of probiotics on 
patient pain.  
  
CONCLUSION: There is conflicting evidence as to whether probiotic supplementation improves 
pain and number of tender joints in adults with rheumatoid arthritis. Further research is needed to 
determine the true effectiveness of probiotic supplementation on pain and number of tender 
joints in patients with rheumatoid arthritis.  
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INTRODUCTION 
 
Rheumatoid Arthritis (RA) is a complicated autoimmune disease which causes systemic 
inflammation, involving multiple joints throughout the body.1 This chronic disease leads to pain, 
cartilage degradation, and deformities. Rheumatoid arthritis causes a wide array of extra-articular 
complications such as pulmonary nodules, myocarditis and arrhythmias, renal failure, anemia, 
and keratoconjunctivitis.2 Cardiovascular disease is a major cause of mortality in those with RA.2 
RA is the most common autoimmune inflammatory arthritis, affecting nearly 1% of people 
worldwide.3 If left untreated, RA can cause permeant disability and shorten one’s life expectancy 
due to the many complications of the disease.3  
 It is estimated that treatment for articular and extra-articular complications of  
rheumatoid arthritis costs the US about $19 billion each year.4 Although an exact cost of 
treatment per year for each patient with RA is unknown, one study showed that Americans with 
RA who are being treated with disease-modifying anti-rheumatic drugs (DMARDs), such as 
methotrexate, incur about $19,000 in treatment cost per year.5 Those with RA are about 10 times 
more likely to be on work disability compared to Americans without RA.6 An exact number of 
health care visits per year for patients with RA is unknown; however, a study with 127 patients 
showed a median of 7.2 office visits per year.7 Corticosteroids, such as prednisone, are typically 
used to bridge a patient to DMARDs. 3 Corticosteroid injections, typically triamcinolone, can 
provide relief if one or two joints are affected. Synthetic DMARDs are the cornerstone of 
treatment, with methotrexate typically being first line, although leflunomide, 
hydroxychloroquine (antimalarial), and tofacitinib can also be used.3 Biologic DMARDs such as 
tumor necrosis factor (TNF) inhibitors like etanercept, infliximab, adalimumab and rituximab are 
typically added to the treatment of those not responding to methotrexate.3  
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Since no cure for rheumatoid arthritis has been found, alternative therapies should be 
researched to bridge the gaps between current treatments. The cause of rheumatoid arthritis is 
unknown, but studies have revealed that RA patients have altered gut microbiomes, suggesting 
gut bacteria to be a possible etiology of RA and proposing that probiotic supplementation may 
have a role in RA treatment.8  Probiotics restore the normal flora needed in our guts for healthy 
digestion. Without this beneficial bacteria in our gut, pathogenic bacteria can overgrow and 
cause inflammation within the body.1 Due to the relationship between gut microbiomes and RA, 
probiotics are being proposed to help decrease rheumatoid arthritis symptoms as a supplemental 
therapy along with DMARDs, corticosteroids, and TNFs. This paper evaluates three randomized 
control trials (RCTs) comparing the efficacy of probiotic supplementation as an adjunctive 
therapy for helping to decrease pain and the number of tender joints in RA. 
OBJECTIVES 
 
The objective of this selective EBM review is to determine whether or not “probiotic 
supplementation helps decrease pain and number of tender joints in adults with rheumatoid 
arthritis?”  
METHODS 
 
From searching on Pubmed with keywords “probiotics” and “rheumatoid arthritis”, three 
randomized control trials (RCTs) were selected based on their credibility and relevance to my 
question. Articles were considered credible if they were published in peer reviewed journals, 
controlled bias through double-blinded randomization, and were reproducible studies. The 
articles needed to measure patient-centered outcomes and be published within the past 10 years, 
from January 2008 to January 2018.  All three articles were published in English and in a peer 
reviewed journal. Inclusion criteria comprised being double-blind, randomized control trials 
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about adults with rheumatoid arthritis symptoms from 2008-2018. Articles were excluded from 
this selective EBM if they included minors <18 years old and had patients without rheumatoid 
arthritis. The summary of statistics reported were through p-values, mean difference from 
baseline, and % change from baseline. In Table 1, the demographics and characteristics of the 
three double blind RCTs can be found.  
Articles were also selected based on meeting the criteria for population, interventions, 
comparison groups, outcomes measured, and type of study.  The population of studies targeted in 
this selective EBM review were adult patients who had been diagnosed with rheumatoid arthritis. 
The interventions used in each study were probiotic strains. Strains varied per study, but all are 
considered probiotic supplementation. These probiotic caplets contained bacteria such as 
Bacillus coagulans, L.casei and maltodexin, and a mixture of lactobacillus acidophilus, 
lactobacillus casei , and Bifidobacterium. While the treatment groups received an oral probiotic 
caplet, the placebo group received a visually similar oral placebo pill. The outcomes measured 
that are discussed in this selective EBM include pain severity and number of tender joints. 
Table1: Demographics & Characteristics of included studies 
 
Study Type #pts Age (yrs) Inclusion Criteria Exclusion Criteria W/D Interventions 
Alipour, 
2014 
(8) 
Double 
blind 
RCT 
60 Between 
20-80yrs 
-Females with RA dx based on the 
American College of 
Rheumatology’s Criteria, for more 
than 1 year who had inactive to 
moderate levels and were under 
treatment with DMARDs 
-Not taking NSAIDs or cytokine 
inhibitors 
 
-Pregnant or lactating, under 
hormone therapy, Dx of 
DM, thyroid disorders, 
kidney or hepatic diseases, 
Cushing’s syndrome, IBD, 
other inflammatory 
disorders, digestive tract 
diseases, lactose intolerance,  
taking antioxidants, 
vitamins, fiber, or omega-3 
supplements 3 weeks prior 
to interventions, using 
antibiotics 1 month prior to 
study, being on a weight 
reduction diet, smoking or 
being exposed to cigarette 
smoke, using other probiotic 
products 
14 Capsule 
containing 108 
colony forming 
units of L.casei 
and maltodexin 
taken once a day 
for 8 weeks 
 
Mandel, 
2010, 
(1) 
Double 
blind 
RCT 
45 Between
36-82 yrs 
- Adult men & women with 
symptoms of RA for at least 1 year 
from outpatient departments of 
Kashan University of Medical 
Sciences 
-Pregnancy 
-Chronic IBD, kidney 
disease, liver disease 
-Exposure to > 10 mg/day of 
prednisolone 
1 Bacillus 
coagulans GBI-
30, 6086 caplet 
once a day for 60 
days 
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-Participants must have had 4 or 
more of the following symptoms: 
Morning stiffness lasting at least 1 
hour (present for at least 6 weeks), 
Soft tissue swelling in 3 or more joint 
areas observed by physicians (present 
for at least 6 weeks), Swelling of the 
proximal interphalangeal, 
metacarpophalangeal, or wrist  joints, 
Symmetric swelling(present for at 
least 6 weeks), Rheumatoid nodules 
(present for at least 6 weeks), The 
presence of rheumatoid factor, 
Radiographic erosions and/or 
periarticular osteopenia in hand 
and/or wrist joints 
-Treatment with other 
probiotics 
 
 
 
Zamani, 
2016 
(9) 
Double 
blind 
RCT 
60 Between 
25-70 
-Patients with RA that met the 
American College of 
Rheumatology’s criteria 
-Were being treated out patiently 
from Kashan University of Medical 
Sciences from October 2015 to 
December 2015 
-Diagnosed with RA 6 months prior 
with moderate and severe disease 
activity (DAS-28 > 3.2) 
 
-Patients who had chronic 
renal failure, renal tubular 
acidosis, or pancreatitis 
-Patients likely to be started 
on biological agents 
-Pregnant or lactating 
women 
-Patients unlikely to come 
for follow up in 3 months 
-Patients unable to read 
numbers and/or unable to 
mark the pain scale 
8 Daily capsule 
with freeze dried 
strains of 
lactobacillus 
acidophilus (2 X 
109 CFU/g) , 
lactobacillus 
casei (2 X 109 
CFU/g) , and 
bifidobacterium 
(2 X 109 CFU/g)  
for 8 weeks 
 
 
OUTCOMES 
 
 The outcomes measured in this selective EBM are the Stanford Health Assessment 
Questionnaire Visual Analog Scale (HAQ VAS) pain scale for pain severity, visual analog scale 
(VAS) pain scale for pain severity, as well as the number of tender joints from baseline to end of 
study, which were counted by a rheumatologist. 
RESULTS 
 
 This selective EBM review evaluates the effects of probiotic supplementation on the 
effects of rheumatoid arthritis. All three RCTs were double blinded so that neither researchers 
nor participants knew who received placebo or intervention. Two studies compared adult men 
and women with RA while another study, Alipour et al., compared adult women with RA.3 Two 
articles evaluate patient pain while the third article discusses number of tender joints. All three 
articles study the effects of probiotic supplementation with other medications such as 
methotrexate and DMARDS, instead of probiotics as a monotherapy.  
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Alipour et al., assessed the number of tender joints from baseline to end of study, counted 
by a rheumatologist. Sixty adult females, between the ages of 20 to 80, were recruited from a 
rheumatology clinic associated with Sinai Hospital in Tabriz, Iran.8 The participants had meet 
the American College of Rheumatology (ACR) criteria for more than 1 year and were currently 
being treated with DMARDs.8 Patients could not be taking NSAIDs or cytokine inhibitors.8 The 
intervention was a capsule containing 108 colony forming units of L.casei and maltodexin which 
was taken once a day for 8 weeks.8 The placebo group received identical capsules containing 
only maltodextrin taken once a day for 8 weeks.8 Adult females were randomly assigned to 
intervention or placebo group, with twenty-four participants being assigned to the placebo group 
and twenty-two in the intervention group. A capsule count was performed at the end of the study 
which indicated that patients had followed the protocol and only took one pill a day for 8 weeks.8 
Baselines characteristics, such as age, height, weight, BMI, menopausal status, education, and 
current medications, showed no statistical significant difference between the placebo and 
probiotic group.8 Of the 60 patients, 14 were noncompliant with the study protocol and therefore 
not included in the final analysis.8 
A Wilcoxon test was used to independently compare changes within the probiotic and 
placebo group from baseline to end of study.8 An ANCOVA analysis was used to compare the 
differences from baseline to end of study between the probiotic and placebo group.8 At the 
conclusion of the study, the authors report a statistical mean difference of 0.72 joints ( 95% CI, 
0.25 to 1.19) from baseline to end of study. The p-value for this measurement is 0.003 which was 
reported as statistically significant.8  This result can be interpreted as the probiotic group had a 
mean difference of 0.72 less tender joints than the placebo group. Although this p-value is 
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statistically significant, it is important to note that 0.72 is not considered a reduction in 1 full 
joint. The authors claim that no adverse effects were reported upon completion of the study.  
Table 2. Effect of 8 weeks of probiotic supplementation on disease activity in females 
with RA8 
Study Mean difference 
(95%) 
Confidence Interval 
(CI) 
P-value 
Alipour  (2014) 0.72  95% CI, 0.25 to 1.19 0.003 
In a study by Mandel et al., 45 adult men and women between the ages of 36 to 82 were 
randomized into intervention or placebo group.1 The participants, a majority of which were 
women, had to have RA for at least one year and were recruited from the same practice.1 Those 
in the probiotic group received Bacillus coagulans GBI-30, 6086 strain everyday for 60 days. 
The intervention capsule contained green tea extract, methylsulfonylmethane, and vitamins and 
minerals, as well as the probiotic itself.1 The placebo group received a matching pill, containing 
microcrystalline cellulose, every day for 60 days.1 Twenty-two participants were analyzed in 
each group. One participant was not analyzed due to starting an antibiotic for an upper 
respiratory infection (URI) during the trial.1  Patients were seen at their primary investigator’s 
office at baseline, 30 days, and 60 days.1 Participants were analyzed based on their improvement 
from baseline to end of study from their pain scale reports which was measured through the 
HAQ VAS pain scale.1 One patient discontinued treatment due to need for antibiotics for an 
upper respiratory infection and was therefore not included in the final analysis.1 
At the conclusion of the study, improvement of pain severity from baseline to end of 
study was documented through the HAQ VAS pain scale with a p-value of 0.046 which was 
statistically significant. The p-value was calculated using a Student t-test which measured the 
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differences from baseline to end of study between the placebo and intervention group.1 It was 
also noted that the intervention group had a reduction of 19.8% in patient pain from baseline to 
end of study.1 Placebo group only had a 1.6% reduction in patient pain.1 It was determined that 
the 19.8% reduction in patient pain was just shy of the ≥20%  reduction needed by the American 
College of Rheumatology (ACR) to meet ACR20 criteria.1 ACR20 criteria helps determine the 
effectiveness of a therapy due to intervention compared to placebo  and is defined as having a 
≥20%  improvement.10 Although these results are statistically significant, it is hard to determine 
if the improvement seen with Bacillus coagulans is based solely off the probiotic itself since 
there were other elements in the intervention group’s capsule, such as vitamins.  
The authors report no serious adverse effects although minor adverse events in the 
intervention group, such as shingles, poison ivy, upper respiratory infection (URI), and leg 
edema were documented.1 However, it was stipulated that these minor adverse events are 
unlikely related to the probiotics. The placebo group also had documented minor adverse evenets 
such as gastroesophageal reflux, URI, and urinary tract infection (UTI) which were also decided 
to be unrelated by the investigator.1 
Table 3. Reduction in patient pain from baseline to end of study1 
Study % change in patient 
pain from baseline 
to end of study 
Confidence Interval 
(CI) 
P-value 
Mandel (2010) 19.8% reduction 95% CI (0.01 to 0.91) 0.046 
Zamani et al., randomly divided 60 study participants, recruited from an outpatient 
practice, into intervention group or placebo group to determine the effects or probiotics on VAS 
pain severity.9 Study participants were adult men and women with RA between the ages of 25-70 
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years old.9 The visual analog scale for pain severity is a horizontal line 100 mm long that has 
points along the line representing different intensities of pain such as no pain to unbearable 
pain.11 The intervention group received probiotic capsules containing Lactobacillus acidophilus, 
Lactobacillus casei, and Bifidobacterium while the placebo group received a visually 
indistinguishable pill that contained starch instead of the probiotic strains.9 Participants took the 
placebo or probiotic pill every day for 8 weeks.  
Patients were assessed at baseline and at the end of the 8 week study and pain was 
evaluated by the VAS pain scale. Eight patients withdrew from the study for personal reasons; 
however, they were still included in the final analysis.9 At the conclusion of the study, it was 
determined that the effects of probiotic supplementation on VAS pain were not significant. A 
5mm difference was reported when comparing the change from baseline to end of study between 
the placebo and probiotic group. The study concluded with a decrease in VAS pain of 16.7mm 
for the probiotic group while the placebo group saw a decrease of 11.7mm.   A repeated 
ANOVA was used to compare the change in pain from baseline to end of study between the 
probiotic group and placebo group.9 The repeated ANOVA produced a p-value of 0.25 which 
was determined to not be statistically significant.9 A CI was not given. The study reports that no 
side effects were encountered following probiotic supplementation.9 
Table 4. Mean change from baseline to end of study for VAS pain9 
Study Mean (± SD) change 
for placebo group 
Mean (± SD) for 
probiotic group 
P-value 
Zamani (2016) -11.7 ±15.5 -16.7±18.1 0.25 
 
DISCUSSION 
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 Rheumatoid arthritis is a systemic life long disease for which there is no cure, supporting 
the need for new medications and supplements. Since there is evidence that those with RA have 
altered gut microbiomes and impaired immune systems, the idea of probiotic supplementation in 
these patients is a plausible one.1 According to the Food and Agriculture Organization of the 
World Health Organization, probiotics can be beneficial to patients when given in correct 
doses.12 Some studies suggest that probiotics, once ingested, can help fight the pathogens in the 
gut that are responsible for intestinal inflammation.1  Probiotics, since classified as supplements, 
do not need FDA approval before marketing.12 Manufacturers of probiotic supplements do, 
however, have to notify the FDA before promoting their product. 12 
 Probiotics can be found in nearly all grocery and vitamin stores in the United States. 
Probiotic supplements are not considered standard treatment for most diseases and therefore are 
considered experimental and not covered by most commercial insurances. Some insurances may 
cover probiotics if ordered by a healthcare professional, but the probiotics will likely not contain 
the strength needed for those with autoimmune diseases. All this information considered, 
probiotics are immensely cheaper than standard RA medications such as DMARDs.  
The three randomized control trials in this review have conflicting results. Alipour et al. 
supports probiotic supplementation; however, this result is not considered clinically significant 
since it concluded an average decrease of less than one tender joint. While probiotics are fairly 
inexpensive with a manageable dosing regime, the minor reduction observed in number of tender 
joints does not justify regular dosing. However, for patients with advanced RA, the chance of a 
small improvement in number of tender joints may make a difference in the quality of life for 
these patients. It is important to note participants who violated protocol procedures were 
excluded from this study’s analyses, making the results very precise. However, these results may 
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not be feasible in real life as not every patient will not be fully compliant. If those 14 who 
violated protocol had not been excluded in the analyses, the study may not have achieved 
statistically significant evidence. Mandel et al., provides a statistically significant p-value for 
patient pain, but this evidence does not meet ACR criteria by having less than a 20% reduction in 
pain, making this study not clinically applicable. Zamani et al. shows no statistically significant 
correlation between the use of probiotics and decrease in pain severity.9 All three of the studies 
had limitations, mainly based off of sample size, length of study and compliance.  
Although all articles studied adults with RA, their age intervals varied from 25-70, 36-82, 
and 20-80.1,8,9. It is unknown if probiotics have more of an impact at specific ages. Alipour et al. 
only discusses the effectiveness of probiotics on only adult females with RA, indicating less 
generalizability to the US population.8 Although RA is more prevalent in women, Mandel et al. 
showed a statistically significant reduction in patient pain in both men and women.1 All three 
articles studied different strains of probiotic supplementation- Bacilllus Coagulans, L. Casei, and 
Lactobacillus.1,8,9Alipour is the only article which doesn’t evaluate patient pain through VAS 
and instead looks at tender joints.8 Two of the studies took place in Iran which may question the 
applicability of the results to different patient populations in different countries. 8,9 The 
intervention pill in Mandel et al. contained vitamins and green tea extract in addition to the 
probiotic strain which may have confounded the results.1 Each of the three studies were 
approximately 2 months in length.1,8,9 Mandel et al. stated that 60 days was long enough to 
determine the effects of probiotics since NSAIDs relief can usually be determined within 60 
days.1 Nevertheless, 60 days is not sufficient when monitoring disease involvement in a chronic 
disease or the long term side effects of probiotics. 1,8,9 
CONCLUSION 
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 There is conflicting information on whether probiotic supplementation improves pain and 
number of tender joints in rheumatoid arthritis patients. Alipour et al. showed a statistically 
significant average decrease in 0.72 tender joints with probiotic supplementation, however this is 
not considered clinically significant as it is not a full joint. Mandel et al. concludes statistical 
significance of probiotic supplementation on reduction in pain severity with a p-value of 0.046, 
but a reduction in 19.8% pain does not meet ACR criteria and is therefore not clinically 
significant.  Zamani et al. showed no statistically significant effect on patient pain. 
 To determine a more concrete answer to whether probiotics have a significant effect on 
rheumatoid arthritis symptoms, there needs to be studies with increased sample sizes and for a 
period of time longer than two months.1,8,9 Rheumatoid arthritis is a chronic disease that patients 
suffer with for years and with studies only conducted for two months, it is difficult to determine 
the long term efficacy of probiotic supplementation as well as any long term side effects. An 
ongoing study over a year or more should be conducted. Each of the three articles in this review 
used different strains of probiotics. A study with multiple intervention groups, comparing the 
effectiveness of different strains of probiotic groups to each other and a placebo group could 
provide even more information. It is also important to note that each of the three studies took 
places overseas so future studies should be conducted in different countries around the world to 
determine the generalizability of the treatment effects to the global population. Future studies 
should also compare the effects of probiotic supplementation on women with RA to men with 
RA to determine if there are any differences between genders.
    
References 
 
1. Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for 
relieving symptoms of rheumatoid arthritis according to a randomized, controlled 
trial. BioMed Central Complementary and Alternative Medicine. 2010;10:1. 
doi:10.1186/1472-6882-10-1. 
 
2. Matteson E , Davis J. Overview of the systemic and nonarticular manifestations of 
rheumatoid arthritis. In Maini R, ed. UpToDate.: UpToDate, 2018. Accessed on October 
6, 2018. 
 
3. Papadakis MA, McPhee S; Rabow MW. Rheumatic, immunologic, and allergic disorders. 
2018. In: Current Medical Diagnosis & Treatment 2018. New York, NY: McGraw Hill 
Medical; 2018: 842-847 
 
4. Freeman J. Rheumatoid Arthritis Treatment Costs. RheumatoidArthritis.org. 
http://www.rheumatoidarthritis.org/treatment/costs/. Published September 26, 2018. 
Accessed October 6, 2018.  
 
5. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in 
patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis & 
Rheumatology. 2003 Oct; 48(10):2750-62. 
 
6. Chaudhari P. The impact of rheumatoid Arthritis and biologics on employers and 
payers. Biotechnology Healthcare. 2008;5(2):37-44. 
 
7. Ward MM. Rheumatology visit frequency and changes in functional disability and pain 
in patients with rheumatoid arthritis. The Journal of Rheumatology. 1997; Jan 24(1): 35-
42. https://www.ncbi.nlm.nih.gov/pubmed/9002008. Accessed November 17, 2018.  
 
8.  Alipour B., Homayouni-Rad A., Vaghef-Mehrabany E., Sharif S.K., Vaghef-Mehrabany 
L., Asghari-Jafarabadi M., Nakhjavani M.R. and Mohtadi-Nia J. Effects of Lactobacillus 
casei supplementation on disease activity and inflammatory cytokines in rheumatoid 
arthritis patients: a randomized double-blind clinical trial. Internal Journal of Rheumatic 
Diseases. 2014;17: 519-527. doi:10.1111/1756-185X.12333 
 
9. Zamani B., Golkar H. R., Farshbaf S., Emadi-Baygi, M., Tajabadi-Ebrahimi M., Jafari P., 
Akhavan R., Taghizadeh M., Memarzadeh MR and Asemi Z. Clinical and metabolic 
response to probiotic supplementation in patients with rheumatoid arthritis: a 
randomized, double-blind, placebo-controlled trial. Internal Journal of Rheumatic 
Disease. 2016; 19: 869-879.  
 
10. Felson, D. A proposed revision to the ACR20: The hybrid measure of American College 
of Rheumatology response. Arthritis & Rheumatism, 57: 193-202. doi:10.1002/art.22552 
 
    
11. Bodian CA, Freedman G, Hossain S, Eisenkraft JB, Beilin Y. The visual analog scale for 
pain: clinical significance in postoperative patients. Anesthesiology. 2001;95(6):1356-
1361.  
 
12. Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of 
probiotic use. Emerging Infectious Diseases. 2010;16(11):1661-1665. 
doi:10.3201/eid1611.100574. 
 
